Showing results (31-40 of 97) with videos related to
Sort By:
Pageof 10
BMC Pediatrics|June 15, 2010
Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)Robbin Itzler, Gary Koch, David O Matson, et al.AIDS Research and Human Retroviruses|July 29, 2003
Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitorsPaul M Coplan, Alexander Nikas, Anthony Japour, et al.Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|January 30, 2002
Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in miceMelpo Christofidou-Solomidou, Arnaud Scherpereel, Charalambos C Solomides, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 8, 2008
HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccineErin K Quirk, Robin Mogg, Deborah D Brown, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 11, 2002
Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adultsBenjamin Young, Margaret A Fischl, Helene M Wilson, et al.The Pediatric Infectious Disease Journal|November 29, 2007
Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infantsMichelle G Goveia, Zoe M Rodriguez, Michael J Dallas, et al.The Pediatric Infectious Disease Journal|May 9, 2007
Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United StatesZoe M Rodriguez, Michelle G Goveia, Jon E Stek, et al.Human Vaccines & Immunotherapeutics|December 9, 2014
Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factorsTessie B McNeely, Najaf A Shah, Arthur Fridman, et al.Cytokine|March 23, 2011
Therapeutic potential of plasma gelsolin administration in a rat model of sepsisTaylor S Cohen, Robert Bucki, Fitzroy J Byfield, et al.Open Forum Infectious Diseases|March 4, 2015
Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/RibavirinJohn A Howe, Jianmin Long, Stuart Black, et al.Pageof 10